1. Preclinical and clinical pharmacology of the GABAA receptor α5 subtype-selective inverse agonist α5IA;Atack;Pharmacol. Ther.,2010
2. L-655,708 enhances cognition in rats but is not proconvulsant at a dose selective for α5-containing GABAA receptors;Atack;Neuropharmacology,2006
3. TPA023 [7-(1,1-dimethylethyl)-6-(2-ethyl-2H-1,2,4-triazol-3-ylmethoxy)-3-(2-fluorophenyl)-1,2,4-triazolo[4,3-b]pyridazine], an agonist selective for α2- and α3-containing GABAA receptors, is a nonsedating anxiolytic in rodents and primates;Atack;J. Pharmacol. Exp. Ther.,2006
4. The plasma-occupancy relationship of the novel GABAA receptor benzodiazepine site ligand, α5IA, is similar in rats and primates;Atack;Br. J. Pharmacol.,2009
5. Atack, J.R., Hallett, D., Tye, S., Wafford, K.A., Ryan, C., Sanabria-Bohórquez, S.M., Eng, W., Gibson, R.E., Burns, H.D., Dawson, G.R., Carling, R.W., Street, L.J., Pike, A., De Lepeleire, I., Van Laere, K., Bormans, G., de Hoon, J.N., Van Hecken, A., McKernan, R.M., Murphy, M.G., Hargreaves, R.J. Preclinical and clinical pharmacology of TPA023B, a GABAA receptor α2/α3 subtype-selective agonist. J. Psychopharmacol., in press-a.